Biocom California’s top priority is the safety of our members and the well-being of our employees. After careful consideration, Biocom California has decided to transform our 2021 Global Life Science Partnering Conference to a fully virtual event. We know that many lives are being impacted and disrupted by COVID-19 and we are grateful to be able to continue offering our members valuable content in a safe manner.
Close
Keynote Speakers:
Kate Bingham, Managing Director, SV Health Investors | Former Chair, UK Vaccine Taskforce (Until January 2021)
John Reed, Executive Vice President, Global Head of Research & Development, Sanofi
Moncef Slaoui, Partner, Medicxi, Former Scientific Head of Operation Warp Speed
Conference Speakers:
Devang Bhuva, Senior Vice President, Corporate Development, Gilead Sciences
Marianne De Backer, PhD, MBA, EVP Global Head, Strategy & Business Development, Bayer
Francesco De Rubertus, Co-Founder and Partner, Medicxi
Jessica Droge, Vice President of Business Development, Amgen
Simone Fishburn, Ph.D., Vice President and Editor in Chief, BioCentury
Carol Gallagher, Pharm. D., Venture Partner, NEA
George Golumbeski, Independent Biotechnology Executive
Henry Gosebruch, Executive Vice President, Chief Strategy Officer, Abbvie
Jason Hafler, Managing Director, Sanofi Ventures
Reza Halse, President, Merck Research Labs Ventures Fund
Faheem Hasnain, Executive Advisor, Vertex Ventures
Richard Heyman, Ph.D., Venture Partner, Arch Ventures; Founder and Executive Chairman of the Board, Metacrine Inc.
Nina Kjellson, General Partner/West Coast, Canaan
Jim Krenn, Partner, Morrison & Foerster, LLP
Angele Maki, Ph.D., Vice President of Emerging Technology & Innovation, Eli Lilly
Oleg Nodelman, Founder and Managing Director, EcoR1 Capital Fund
Carole Nuechterlein, Head, Roche Venture Fund
Merdad Parsay, Chief Medical Officer, Gilead Sciences
Heather Preston, Managing Partner, Pivotal
Kyle Rasbach, Managing Partner, Pappas Ventures
Terry Rosen, Chief Executive Officer, Arcus
Camille Samuels, Partner, Venrock
Ioannis Sapountzis, Ph.D, Corporate Senior Vice President, Business Development, Boehringer Ingelheim Pharmaceuticals, Inc.
Uwe Schoenbeck, Ph.D, Senior Vice President and Chief Scientific Officer, Emerging Science and Innovation (ES&I), Pfizer Worldwide Research, Development, and Medical
Andrew Schwab, Managing Partner, 5am Ventures
Armen Shanafelt, Ph.D., General Partner, Lilly Ventures
Nigel Sheail, Global Head, Mergers & Acquisitions and Business Development & Licensing, Novartis
Kumar Srinivasan, Vice President, Global Head of Business Development & Licensing, Biopharmaceuticals R&D, AstraZeneca
Alex Szidon, Vice President and Head of Business Development, gRED, Genentech
Ben Thorner, SVP and Head of BD&L, Merck
Arda Ural, Americas Life Science & Healthcare Markets Leader, Ernst & Young
Jeffrey Warmke, Ph.D, Senior Vice President, Search and Evaluation & Alliance Management, Global Business Development, Daiichi Sankyo